| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:22488762 | IVR | 1 mg | 1 mg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg | 1 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| PMID:23239441 | IVR | 0.1 mg | 0.1 mg | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg | 0.1 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Causes masculinized behavior | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:31131507 | IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations |
| IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.142857142857143 mg/kg/day | 0.142857142857143 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.